Open AccessSerum miR-192-5p levels predict the efficacy of pegylated interferon therapy for chronic hepatitis B
Author(s) -
Yoshihito Nagura,
Kiyotaka Matsuura,
Etsuko Iio,
Koji Fujita,
Tomoyuki Inoue,
Akihiro Matsumoto,
Eiji Tanaka,
Shuhei Nishiguchi,
Jae-Heon Kang,
Takeshi Matsui,
Masaru Enomoto,
Hiroki Ikeda,
Tsunamasa Watanabe,
Chiaki Okuse,
Masataka Tsuge,
Masanori Atsukawa,
Masao Tateyama,
Hiromi Kataoka,
Yasuhito Tanaka
Publication year - 2022
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0263844
Subject(s) - medicine , hbeag , pegylated interferon , hepatitis b virus , hepatitis b , gastroenterology , immunology , odds ratio , biomarker , antigen , alpha interferon , interferon , viral load , chronic hepatitis , virus , hbsag , ribavirin , biology , biochemistry
We examined the association between serum miRNA (-192-5p, -122-3p, -320a and -6126-5p) levels and the efficacy of pegylated interferon (Peg-IFN) monotherapy for chronic hepatitis B (CHB) patients. We enrolled 61 CHB patients treated with Peg-IFNα-2a weekly for 48 weeks, of whom 12 had a virological response (VR) and 49 did not VR (non-VR). A VR was defined as HBV DNA < 2,000 IU/ml, hepatitis B e antigen (HBeAg)-negative, and nucleos(t)ide analogue free at 48 weeks after the end of treatment. The non-VR group showed a significantly higher HBeAg-positivity rate, ALT, HBV DNA, and serum miR-192-5p levels at baseline ( P = 0.024, P = 0.020, P = 0.007, P = 0.021, respectively). Serum miR-192-5p levels at 24-weeks after the start of treatment were also significantly higher in the non-VR than the VR group ( P = 0.011). Multivariate logistic regression analysis for predicting VR showed that miR-192-5p level at baseline was an independent factor (Odds 4.5, P = 0.041). Serum miR-192-5p levels were significantly correlated with the levels of HBV DNA, hepatitis B core-related antigen, and hepatitis B surface antigen (r = 0.484, 0.384 and 0.759, respectively). The serum miR-192-5p level was useful as a biomarker for the therapeutic efficacy of Peg-IFN in CHB treatment.